Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABBV-400 (Primary) ; Bevacizumab (Primary)
  • Indications Acral lentiginous melanoma; Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Uterine cancer
  • Focus First in man; Therapeutic Use
  • Sponsors AbbVie

    • Most Recent Events

    • 04 Jun 2024 Results (n=122, data cut-off October 2023) assessing safety and preliminary efficacy of ABBV-400 from dose escalation (ESC) and expansion (EXP) cohorts in CRC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2024 Results assessing exposure-response analyses to determine optimal monotherapy dose in mCRC patients, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
    • 28 May 2024 According to an AbbVie media release, data from this trial will be presented at the at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 31 - June 4, 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top